Research progress of PD-1/PD-L1 inhibitors in ovarian cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 312-315, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-863481
ABSTRACT
Ovarian cancer has the characteristics of difficulty in early diagnosis, easy recurrence and resistance, so its mortality rate ranks first in gynecological tumors. Existing treatment methods such as surgery, radiotherapy and chemotherapy are not very effective, thus immunotherapy has emerged. Immune checkpoint programmed death-1 (PD-1) and its ligand PD-L1 can inhibit T cell proliferation and mediate tumor immune escape. At present, PD-1/PD-L1 inhibitors have made breakthrough progress in a variety of solid tumors, and they have achieved initial efficacy in clinical treatment of ovarian cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio de tamizaje
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS